---
document_datetime: 2024-01-16 13:15:52
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/brintellix-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: brintellix-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 6.6642762
conversion_datetime: 2025-12-22 21:04:19.607141
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Brintellix

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                              |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0040              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                           | 10/01/2024                          |                                             | SmPC                             |                                                                                                                                                                                      |
| II/0038              | Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to include clinically relevant information on the efficacy, safety, tolerability, and | 14/09/2023                          | 18/10/2023                                  | SmPC and PL                      | Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC to include clinically relevant information on the efficacy, safety, tolerability, and PK of vortioxetine in the paediatric |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | PK of vortioxetine in the paediatric population based on final results from studies 12709A, 12712A and 12712B. Study 12709A is an interventional, randomized, double-blind, placebo-controlled, active-reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major Depressive Disorder (MDD) to evaluate efficacy and safety. Whereas studies 12712A and 12712B are 2 open-label, long-term safety and efficacy studies in children and adolescents: one 6-month extension study (Study 12712A) to Studies 12709A and 12710A, and one 18-month extension study (Study 12712B) to Study 12712A. In addition, updates are proposed in section 4.5 and package leaflet section 2 in relation to NSAIDs as well as updates to the Package leaflet section 4 to align SmPC wording on sexual dysfunction. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |            |                        | population based on final results from studies in children and adolescents. The Package Leaflet is updated accordingly. In addition, updates are proposed in the package leaflet in relation to NSAIDs as well as on sexual dysfunction to align SmPC wording. Please refer to Scientific Discussion 'Product Name-H-C- Product Number-II-Var.No' BRINTELLIX- /H/C/002717/II/0038 For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10052 /202209 | Periodic Safety Update EU Single assessment - vortioxetine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 25/05/2023 | 26/07/2023 | SmPC, Labelling and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10052/202209.                                                                                                                                                                                                                                                                                                                        |
| II/0033             | B.II.b.1.d - Replacement or addition of a manufacturing site for the FP - Site which requires an initial or product specific inspection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15/06/2023 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| II/0037   | Please refer to the Recommendations section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 09/02/2023   | n/a   | For more information, please refer to the Summary of Product Characteristics.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------------------------------------------------------------------------|
| IB/0034   | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 19/04/2022   | n/a   |                                                                                 |
| IA/0036   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                               | 08/04/2022   | n/a   |                                                                                 |
| IA/0035/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 08/04/2022   | n/a   |                                                                                 |

<div style=\"page-break-after: always\"></div>

| IB/0031             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 08/09/2021   | 12/08/2022   | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10052 /202009 | Periodic Safety Update EU Single assessment - vortioxetine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20/05/2021   | 16/07/2021   | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10052/202009.                                                                                                                                                                                                                                                                                                                                                                             |
| IAIN/0028           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/12/2020   | 16/07/2021   | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0025             | Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC to reflect the outcomes of the paediatric clinical study 12710A (a paediatric efficacy and safety study in adolescent MDD patients) and the study 12708A (paediatric pharmacokinetics and tolerability study in children and adolescent patients with DSM-IV diagnosis of depressive and anxiety disorder). In addition, the MAH took the opportunity to propose minor amendments to the labelling and to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 17/09/2020   | 18/11/2020   | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Product Name-H-C- 002717-II-Var.0025' SmPC new text Update of the Product Information to reflect the outcomes of the paediatric clinical study 12710A (a paediatric efficacy and safety study in adolescent MDD patients) and the study 12708A (paediatric pharmacokinetics and tolerability study in children and adolescent patients with DSM-IV diagnosis of depressive and anxiety disorder). For more information, please refer to the Summary of Product Characteristics. |
| PSUSA/10052 /201909 | Periodic Safety Update EU Single assessment - vortioxetine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 30/04/2020   | 03/07/2020   | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10052/201909.                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0027             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 13/05/2020   | n/a          |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0026   | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/04/2020 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0022/G | This was an application for a group of variations. Update of section 5.1 of the SmPC to describe the effects of vortioxetine on treatment-emergent sexual dysfunction based on the outcome of the clinical studies 318 and 4001. Update of sections 4.4 and 5.2 to reflect the outcome of pharmacokinetic study 401 in subjects with severe hepatic impairment. Section 4.2 is also updated to add a cross reference to section 4.4 and 5.2 for hepatic impairment and section 4.4 wording for renal impairment is aligned to the one regarding hepatic impairment. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 16/01/2020 | 03/07/2020 | SmPC | In the iMAA of Brintellix (vortioxetine), to ensure a systematic evaluation of sexual dysfunction besides the spontaneous collection of adverse events (AEs), the Arizona Sexual Experiences Scale (ASEX) was used in a number of studies. In addition to the spontaneously reported AEs, the proportion of subjects who shifted from normal to abnormal according to the ASEX is described in the SmPC. These data indicate that the risk of developing Treatment-Emergent Sexual Dysfunction (TESD) with vortioxetine is low. In order to further investigate the risk of developing Treatment-Emergent Sexual Dysfunction (TESD) with vortioxetine, two active-comparator clinical studies 318 and 4001 were performed. The CHMP agrees to reflect the outcome of these studies in section 5.1 of the SmPC. Study 401 investigated the pharmacokinetics of vortioxetine and its metabolites in subjects with severe hepatic impairment. The CHMP agrees to reflect the outcome of the study in section 5.2 of the SmPC and update section 4.4 regarding the limited data available and caution to be exercised when treating patients with hepatic impairment. |

<div style=\"page-break-after: always\"></div>

| IAIN/0023/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site   | 20/09/2019   | n/a        |                        |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10052 /201809 | Periodic Safety Update EU Single assessment - vortioxetine                                                                                                                                                                                               | 26/04/2019   | 28/06/2019 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10052/201809. |
| R/0019              | Renewal of the marketing authorisation.                                                                                                                                                                                                                  | 20/09/2018   | 20/11/2018 | SmPC, Labelling and PL |                                                                                                                                            |
| IB/0020             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                           | 18/07/2018   | 20/11/2018 | SmPC and PL            |                                                                                                                                            |
| PSUSA/10052 /201709 | Periodic Safety Update EU Single assessment - vortioxetine                                                                                                                                                                                               | 12/04/2018   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                          |
| IB/0017             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                           | 06/12/2017   | 20/11/2018 | SmPC, Labelling and PL |                                                                                                                                            |
| IB/0014             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                     | 18/05/2017   | n/a        |                        |                                                                                                                                            |
| PSUSA/10052 /201609 | Periodic Safety Update EU Single assessment - vortioxetine                                                                                                                                                                                               | 05/05/2017   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IA/0016/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation   | 03/05/2017   | n/a        |                        |                                                                                                                                            |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0015             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                           | 27/04/2017   | n/a        |                        |                                                                                                                                            |
| PSUSA/10052 /201603 | Periodic Safety Update EU Single assessment - vortioxetine                                                                                                                                                                                                                                                                                                                                             | 10/11/2016   | 11/01/2017 | PL                     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10052/201603. |
| IB/0011             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                              | 24/05/2016   | 11/01/2017 | SmPC, Labelling and PL |                                                                                                                                            |
| PSUSA/10052 /201509 | Periodic Safety Update EU Single assessment - vortioxetine                                                                                                                                                                                                                                                                                                                                             | 14/04/2016   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10052 /201503 | Periodic Safety Update EU Single assessment - vortioxetine                                                                                                                                                                                                                                                                                                                                             | 08/10/2015   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IB/0008             | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                            | 17/06/2015   | 24/02/2016   | SmPC and PL            |                                                                                                                                                                                                                                                                                       |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0007             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                 | 06/05/2015   | 24/02/2016   | SmPC                   |                                                                                                                                                                                                                                                                                       |
| PSUSA/10052 /201409 | Periodic Safety Update EU Single assessment - vortioxetine                                                                                                                                                                                                                | 10/04/2015   | n/a          |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                     |
| II/0004             | Update of section 5.1 of the SmPC with information on the effect of vortioxetine on certain aspects of cognitive function in Major Depressive Disorder. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/02/2015   | 24/02/2016   | SmPC                   | Effect of vortioxetine on certain aspects of cognitive function in Major Depressive Disorder have been included in the SmPC further to data analysis, including results obtained with vortioxetine in Major Depressive Disorder (MDD) patients presenting with cognitive dysfunction. |
| IB/0005             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                            | 18/12/2014   | n/a          |                        |                                                                                                                                                                                                                                                                                       |
| PSUV/0003           | Periodic Safety Update                                                                                                                                                                                                                                                    | 23/10/2014   | 16/12/2014   | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0003.                                                                                                                                                     |
| IAIN/0002/G         | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within                                                                    | 07/03/2014   | 16/12/2014   | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes   |            |            |                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IAIN/0001 | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                     | 07/03/2014 | 16/12/2014 | SmPC, Labelling and PL |